ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

June 20, 2024

https://www.globenewswire.com/news-release/2024/06/20/2901707/25687/en/ClearPoint-Neuro-Congratulates-Partner-Aspen-Neuroscience-on-Use-of-the-ClearPoint-Navigation-System-for-All-Enrolled-Patients-in-ASPIRO-Clinical-Trial.html

SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner Aspen Neuroscience, Inc. on use of the ClearPoint Neuro Navigation System to transplant dopaminergic neuron precursor cells (DANPCs) for all enrolled patients with Parkinson’s Disease (PD) in its recently launched ASPIRO Phase 1/2a clinical trial. ASPIRO is an open label trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe PD.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.